(R)-3-羟甲基吗啉盐酸盐 | 1212377-10-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: (R)-3-羟甲基吗啉盐酸盐
• 中文别名: (R)-吗啉-3-基甲醇盐酸盐
• 英文名称: [(3R)-morpholin-3-yl]methanol hydrochloride
• 英文别名: (R)-morpholin-3-ylmethanol hydrochloride；[(3R)-morpholin-3-yl]methanol;hydrochloride
• CAS: 1212377-10-0
• 化学式: C₅H₁₁NO₂*ClH
• mdl: MFCD09910295
• 分子量: 153.609
• InChiKey: WFLUDHYXVXRFLY-NUBCRITNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.04
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  41.5
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (R)-Morpholin-3-ylmethanol, HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (R)-Morpholin-3-ylmethanol, HCl
CAS number: 1212377-10-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H11NO2.ClH
Molecular weight: 153.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (R)-3-羟甲基吗啉盐酸盐 在 potassium hydroxide 作用下， 以 二甲基亚砜 为溶剂， 反应 19.0h， 以18%的产率得到(4aS)-8-nitro-2,4,4a,5-tetrahydro-1H-[1,4]oxazino[3,4-c][1,4]benzoxazine
  参考文献：
  名称：

  COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP

  摘要：

  提供了一类含有三环杂环基团的化合物。具体来说，提供了结构如下式（I）所代表的化合物（每个基团如规范中定义），含有该式（I）化合物的药物组合物，以及它们的同位素衍生物、手性异构体、变构体、不同盐类、前药、制剂等。它可以有效抑制蛋白激酶（如EGFR、FAK、SYK、FLT-3、Axl、CDK、JAK等），从而治疗各种肿瘤、非酒精性脂肪肝病（NASH）、肺纤维化（IPF）和相关多种疾病。

  公开号：

  US20190308993A1
• 作为产物：
  描述：

  (3R)-3-(羟甲基)吗啉-4-羧酸叔丁酯 在 盐酸 作用下， 以 1,4-二氧六环 、 氯仿 为溶剂， 反应 3.0h， 生成 (R)-3-羟甲基吗啉盐酸盐
  参考文献：
  名称：

  COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP

  摘要：

  提供了一类含有三环杂环基团的化合物。具体来说，提供了结构如下式（I）所代表的化合物（每个基团如规范中定义），含有该式（I）化合物的药物组合物，以及它们的同位素衍生物、手性异构体、变构体、不同盐类、前药、制剂等。它可以有效抑制蛋白激酶（如EGFR、FAK、SYK、FLT-3、Axl、CDK、JAK等），从而治疗各种肿瘤、非酒精性脂肪肝病（NASH）、肺纤维化（IPF）和相关多种疾病。

  公开号：

  US20190308993A1

文献信息

• [EN] MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE<br/>[FR] MODULATEURS DE L'HÉMOGLOBINE POUR LE TRAITEMENT DE LA DRÉPANOCYTOSE
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2020072377A1

  公开（公告）日：2020-04-09

  The present disclosure relates to compounds of the general formula (I) and pharmaceutical compositions containing them. The compounds are suitable as modulators of hemoglobin and thus useful in treating disorders mediated by hemoglobin such as sickle cell disease.

  本公开涉及一般式（I）化合物及含有它们的药物组合物。这些化合物适用作血红蛋白调节剂，因此在治疗由血红蛋白介导的疾病如镰状细胞病中有用。
• [EN] COMPOUNDS THAT INHIBIT MCL-1 PROTEIN<br/>[FR] COMPOSÉS INHIBANT LA PROTÉINE MCL-1
  申请人：AMGEN INC

  公开号：WO2018183418A1

  公开（公告）日：2018-10-04

  Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (I), or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

  本文提供了髓样细胞白血病1蛋白（Mcl-1）抑制剂，其制备方法，相关的药物组合物，以及使用这些物质的方法。例如，本文提供了化合物的化学式（I）或其立体异构体；以及这些化合物的药用盐和含有这些化合物的药物组合物。本文提供的化合物和组合物可以用于治疗癌症等疾病或症状。
• FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF
  申请人：FORUM Pharmaceuticals Inc.

  公开号：US20170044182A1

  公开（公告）日：2017-02-16

  The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.

  本公开涉及融合吗啉吡嘧啶类化合物，包括有效量的融合吗啉吡嘧啶类化合物的药物组合物，以及在治疗神经退行性疾病中使用融合吗啉吡嘧啶类化合物的方法，包括向需要的受试者施用有效量的融合吗啉吡嘧啶类化合物。
• [EN] NOVEL HEPATITIS C VIRUS INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：MEDIVIR AB

  公开号：WO2013095275A1

  公开（公告）日：2013-06-27

  The invention provides compounds of formula (I): wherein Rings A and A' are independently 5-membered optionally substituted aromatic heterocycles; Q is C(=O)NR1R1' or formula U is C(R4)2, O, S, S(=O)2, C(R4)2C(R4)2, CH2O, OCH2, CH2S, SCH2, CH2S(=O)2, S(=O)CH2 or C=C(Ru )2; X is CH2, CHR12, CR12R12, O, S, S(=O)2 or NRx; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

  本发明提供了式(I)的化合物：其中环A和A'独立地是5个成员的可选取代的芳香杂环；Q是C(=O)NR1R1'或式U是C(R4)2，O，S，S(=O)2，C(R4)2C(R4)2，CH2O，O ，CH2S，S ， (=O)2，S(=O)CH2或C=C(Ru)2；X是 ，CHR12，CR12R12，O，S，S(=O)2或NRx；m是0，1，2或3；n是0，1，2或3；其他变量如权利要求中所定义，用于治疗或预防丙型肝炎病毒感染，以及相关方面。
• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2018137573A1

  公开（公告）日：2018-08-02

  Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

  提供的是抑制LRRK2激酶活性的新化合物，它们的制备过程，包含它们的组合物以及它们在治疗或预防与LRRK2激酶活性相关或以其为特征的疾病中的用途，例如帕金森病、阿尔茨海默病和肌萎缩侧索硬化症（ALS）。